This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Black, M.E., Newcomb, T.G., et al., 1996, Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy, Proc. Natl. Acad. Sci., USA, 93:3525–3529.
Borelli, E., Heyman, R., et al., 1988, Targeting of an inducible toxic phenotype in animal cell., Proc. Natl. Acad. Sci., USA, 85:7572–7576.
Bridgewater, G., Springer, C.J., et al., 1995, Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954, Eur. J. Cancer, 31A:2362–2370.
Chen, L., and Waxman, D.J., 1995, Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: Development of a combined chemotherapy/cancer gene therapy strategy, Cancer Res., 55:581–589.
Culver, K.W., 1996, The role of herpes simplex thymidine kinase gene transfer in the drug treatment of brain tumors, CNS Drugs, 6:1–11.
Culver, K.W., Ram, Z., et al., 1992, In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors, Science, 256:1550–1552.
Ebbinghaus, S.W., Vigneswaran, N., et al., 1996, Efficient delivery of triplex forming oligonucleotides to tumour cells by adenovirus-polylysine complexes, Gene Ther., 3:287–297.
Freeman, S.M., Abboud, C.N., et al., 1993, The “bystander effect”: Tumor regression when a fraction of the tumor mass is genetically modified, Cancer Res., 53:5274–5283.
Friedlos, F., Denny, W.A., et al., 1997, Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy, J. Med. Chem., 40:1270–1275.
Gagandeep, S., Brew, R., et al., 1996, Prodrug-activated gene therapy: Involvement of an immunological component in the “bystander effect”, Gene Ther., 3:83–88.
Glorioso, J.C., DeLuca, N.A., et al., 1995, Development and application of herpes simplex virus vectors for human gene therapy, Annu. Rev. Microbiol., 49:675–710.
Huber, B.E., Austin, E.A., et al., 1994, Metabolism of 5-fluorocytidine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase, Proc. Natl. Acad. Sci., USA, 91: 8302–8306.
Huber, B.E., Richards, C.A., et al., 1995, VDEPT; An enzyme/prodrug gene therapy approach for the treatment of metastatic colorectal cancer, Advanced Drug Delivery Reviews, 17:279–292.
Kanai, F., Shiratori, Y., et al., 1996, Gene therapy for α-fetoprotein producing human hepatoma cells by adenovirus mediated transfer of the herpes simplex virus thymidine kinase gene, Hepatology, 23: 1359–1368.
Kojima, A., Hackett, N.R., et al., 1998, In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for localtreatment of solid tumours, Journal of Clinical Investigations, 101:1789–1796.
Kremer, E.J., and Perricaudet, M., 1995, Adenovirus and AAV mediated gene transfer, Br. Med. Bull, 51: 31–44.
Marais, R., Spooner, R.A., et al., 1996, Gene-directed enzyme prodrug therapy with a mustard prodrug/ carboxypeptidase G2 combination, Cancer Res., 56:4735–4742.
Marais, R., Spooner, R.A., et al., 1997, A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy, Nature Biotechnology, 15:1373–1377.
McNeish, I.A., Green, N.K., et al., 1998, Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954, Gene Ther., 5:1061–1069.
Miller, A.D., 1998, Cationic liposomes for gene therapy, Angewandte Chemie, International Edition, 37:1768–1785.
Niculescu-Duvaz, D, Niculescu-Duvaz, I., et al., 1998, Self-immolative mustard prodrugs for suicide gene therapy, J. Med. Chem.
Niculescu-Duvaz, I., Spooner, R., et al., 1998, Gene-directed enzyme prodrug therapy, Bioconj. Chem., 9: 4–22.
Pavlovic, J., Nawrath, M., et al., 1996, Anti-tumor immunity is involved in the thymidine kinase-mediated killing of tumors induced by activated Ki-ras (G12V), Gene Ther., 3:635–643.
Rainov, N.G., Dobberstein, K.-U., et al., 1998, New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol, Human Gene Ther., 9:1261–1273.
Roth, J.A., and Cristiano, R.J., 1997, Gene therapy for cancer: What have we done and where are we going?, Journal of the National Cancer Institute, 89:21–39.
Spooner, R.A., Deonarain, M.P., et al., 1995, DNA vaccination for cancer treatment, Gene Ther., 2:173–180.
Sterman, D., H., Treat, J., et al., 1998, Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of phase I clinical trial in malignant mesothelioma, Human Gene Ther., 9:1083–1092.
Vile, R.G., Diaz, R.M., et al., 1995, Tissue-specific gene expression from Mo-MLV retroviral vectors with hybrid LTRs containing the murine tyrosinase enhancer/promoter, Virol., 214:307–313.
Vile, R.G., and Hart, I.R., 1993b, Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA, Cancer Res., 53:3860–3864.
Wadha, M.S., Collard, W.T., et al., 1997, Peptide-mediated gene delivery: influence of peptide structure on gene expression, Bioconj. Chem., 8:81–88.
Wei, M.X., Tamiya, T., et al., 1994, Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450-2B1 gene, Human Gene Ther., 5:969–978.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Kluwer Academic Publishers
About this chapter
Cite this chapter
Springer, C.J., Niculescu-Duvaz, I. (2002). Approaches to Gene-Directed Enzyme Prodrug Therapy (GDEPT). In: Habib, N.A. (eds) Cancer Gene Therapy. Advances in Experimental Medicine and Biology, vol 465. Springer, New York, NY. https://doi.org/10.1007/0-306-46817-4_35
Download citation
DOI: https://doi.org/10.1007/0-306-46817-4_35
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-306-46191-0
Online ISBN: 978-0-306-46817-9
eBook Packages: Springer Book Archive